Evidence map›Paper›PMID 41142927›Full record

ArticleJournal of market access & health policy2025

A Data-Driven Approach for Estimating Type 2 Diabetes-Related Costs in Greece.

Elisavet Nika, Thomas Tsiampalis, Athanasios Sachlas, Evangelos Liberopoulos, Sotirios Bersimis, Dimitrios Georgakellos

Abstract read
In one paragraph

Article in Journal of market access & health policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Elisavet NikaDepartment of Business Administration, University of Piraeus, 80 Karaoli & Dimitriou Str., 18534 Piraeus, Greece; sbersim@unipi.gr (S.B.); dgeorg@unipi.gr (D.G.).
Thomas TsiampalisDepartment of Nutrition and Dietetics, Harokopio University, El. Venizelou 70, 17676 Athens, Greece; ttsiampalis@uth.gr.ORCID https://orcid.org/0000-0002-4625-460X
Athanasios SachlasDepartment of Computer Science and Biomedical Informatics, University of Thessaly, Papasiopoulou 2-4, 35131 Lamia, Greece; asachlas@uth.gr.ORCID https://orcid.org/0000-0003-0546-3162
Evangelos Liberopoulos1st Department of Internal Medicine, School of Medicine, National and Kapodistran University of Athens, 17 Agiou Thoma Str., 11527 Athens, Greece; elibero@med.uoa.gr.ORCID https://orcid.org/0000-0002-7162-3323
Sotirios BersimisDepartment of Business Administration, University of Piraeus, 80 Karaoli & Dimitriou Str., 18534 Piraeus, Greece; sbersim@unipi.gr (S.B.); dgeorg@unipi.gr (D.G.).ORCID https://orcid.org/0000-0002-7448-1172
Dimitrios GeorgakellosDepartment of Business Administration, University of Piraeus, 80 Karaoli & Dimitriou Str., 18534 Piraeus, Greece; sbersim@unipi.gr (S.B.); dgeorg@unipi.gr (D.G.).ORCID https://orcid.org/0000-0002-7956-4727

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes (T2D) constitutes a major health problem, reaching alarming rates over the last decades, especially due to contemporary lifestyle and associated obesogenic environments, as well as the aging population. Diabetes not only causes social consequences but also leads to increasing healthcare costs, posing a significant challenge for the health system. This paper applies a five-step approach for estimating T2D-related costs in Greece. The approach initially estimates the T2D-related ICD10 prevalence and the target population. Next it applies the appropriate therapeutic protocols to identify the most appropriate treatments. Subsequently, it calculates the total cost of medical treatments for each target population, based on the distribution of patients between the different treatments and treatment lines. Finally, based on the diagnostic and treatment protocols, it calculates the annual direct costs associated with the cost categories. Using the estimated future population of the country, the proposed methodology can also project the budget required, under certain conditions, to deal with T2D. The analysis estimated that T2D-related costs in 2021 under rational use of resources were EUR 1,397,871,172.55 billion and EUR 1,512,934,947.63 billion projected in the year 2030 considering the aging effect, per cost category, and in total, presenting an increase of approximately 115 million euros in 2030 compared to 2021. The term "rational use of resources" in this study refers to the use of internationally recognized, evidence-based diagnostic and therapeutic protocols, as adopted by the Greek Ministry of Health. This scenario represents an idealized standard of care rather than actual real-world adherence and is used to estimate the potential resource needs under optimal medical practice conditions. An inflation rate of 4.2% was applied to costs between 2021 and 2030. The analysis showed that the highest percentage (39%) of the total T2D-related healthcare expenditures is associated with complications that occur in T2D patients. Despite a comparatively modest prevalence of T2D in Greece relative to other European and Mediterranean countries, the economic burden associated with its management remains high. The aging of the population will lead to an increase in the total cost of T2D. The applied methodology of estimating budgets by aggregating categories of expenses under a specific disease (ICD10), instead of dividing budgets into categories of expenses, can successfully lead to the optimization and rationalization of expenses according to actual needs. The findings underline the significant economic burden of T2D in Greece, particularly due to complications and population aging. These results emphasize the urgent need for health policy strategies focusing on prevention, early intervention, and the efficient allocation of healthcare resources. The methodology applied can serve as a decision-making tool for forecasting healthcare budgets and optimizing expenditures under different population and treatment scenarios.

Indexed as

aging effectbudgets’ optimization strategyhealthcare budgetsmeta-analysistype 2 diabetes

Identifiers

PMID41142927
PMCPMC12551024

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.